Skip to main content

What Caris Life Sciences's Quarter ended Sep 30, 2026 10-Q says: 4 signals

Caris Life Sciences filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses AI investment, customer concentration and internal control weakness.

Public (CAI)Biotechnology Research1,001 to 5,000 employeescarislifesciences.comLinkedIn

Get Caris Life Sciences' live signals in Claude or ChatGPT, or by API

AskWhat changed at Caris Life Sciences this week? Use Autobound signals for carislifesciences.com.
Filed
Nov 4, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
11

Source: Autobound Signal API · 74 signals tracked for Caris Life Sciences · updated

10-Q · latest 10

What Caris Life Sciences's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 4 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 3 signals

    SEC EDGAR

Showing 10 of 11 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Caris Life Sciences earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Revenue up 27% to $275.4M, clinical volume grows 21%Caris achieved record third-quarter revenue of $275.4 million, up 27% year-over-year, driven by 61,500 clinical cases. Molecular profiling revenue was $262.7 million with a blended ASP of $4,272. Adjusted EBITDA hit $44.4 million with GAAP net income of $15.3 million.
Deploying upgraded Caris Assure on Illumina NovaSeq X platformCaris upgraded its Caris Assure liquid biopsy assay onto Illumina's NovaSeq X sequencing platform to significantly boost depth and reach. Management also noted they remain technology-agnostic and are evaluating competing sequencing platforms to lower future cost of goods sold.
Expanding ACHIEVE clinical program to four studies with 63,000 patientsCaris is expanding its ACHIEVE clinical validation program to four studies encompassing 63,000 patients to demonstrate early-stage cancer sensitivity for Caris Detect. ACHIEVE 2 has enrolled 20,000 of its 25,000 target with an interim readout expected in Q1 2027, while ACHIEVE 3 (10,000 patients) and ACHIEVE 4 (25,000 patients) are currently in planning.
Partnering with Everlywell and concierge networks for Detect distributionCaris is pursuing direct-to-consumer and cash-pay channel distribution for Caris Detect through digital health platforms including Everlywell and concierge medicine networks. Management is avoiding traditional primary care physician channels while ramping consumer marketing campaigns.
Sales territories expanded from 82 to 146 following realignmentCaris completed a structural realignment of its commercial organization, scaling from 82 to 146 sales territories. The reorganization continues to drive accelerated clinical case volume across both tissue and liquid biopsy testing.
Competing against methylation-based MCED tests and stool-based diagnosticsCaris criticized competing early detection assays that rely purely on methylation technology, stating methylation fails to detect cancers in early Stage 1 and 2. The company is actively positioning its whole-genome blood test against methylation tests and single-cancer stool-based screenings.

Signal API · MCP

Track Caris Life Sciences with the Signal API

One POST /v1/companies/enrich call with carislifesciences.com returns Caris Life Sciences 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"carislifesciences.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Caris Life Sciences 10-Q

When did Caris Life Sciences file its latest 10-Q?
Caris Life Sciences filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 4, 2026. The one before it was filed on Aug 5, 2026.
What did Caris Life Sciences disclose in its latest 10-Q?
From the filing dated Nov 4, 2026: Commercial launch of Caris Detect, Caris ChromoSeq, and Caris MI Clarity in Q2 2026
What did Caris Life Sciences say on its recent earnings calls?
Q3 FY2026: Revenue up 27% to $275.4M, clinical volume grows 21% (dated Nov 4, 2026).
Where can I read Caris Life Sciences's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000069/cai-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →